Audit: QRS - Evening Primrose Oil for Health & Longevity

Audit conducted on 18/08/2026 02:33 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses (1-3 g oil, 70-300 mg GLA; 1.4-2.8 g GLA, 14-28 g oil), time values (4-8 weeks, 12 months, 8-24 weeks), all 8 biomarker targets, all gate items, benefit and risk tier items trace to ER lines 254-475.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s “No established target; track change from the individual’s own baseline” (ER line 451) is carried as “No established target; track change from own baseline”; speculative tiers retained as speculative.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications, “Monitor”/”Caution” interactions remain under Key Interactions; at-a-glance “Eczema and breast pain do not hold up” matches ER Conclusion line 496.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate contents come from ER Key Interactions & Contraindications (lines 314-340); no Benefit-/Risk-Modifying Factor bullet appears in any gate or tier list.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no author names, no supplement brand names anywhere in the QRS; drug names in the interaction gate are the ER’s own examples.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, sceptical register matching the ER; the narrower-than-promised framing of the ER Conclusion is preserved in the at-a-glance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Technical terms are paired with plain-language glosses (e.g., “International normalised ratio (clotting-time ratio)”), and the sheet is oriented to actionable decisions.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as noun-phrase facts and thresholds rather than instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend” or “advise” appears in the document body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Time-to-effect sub-line states “No movement by 12 weeks at an adequate dose argues against continuing” — an inference drawn from ER line 399, not an instruction.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	“placenta praevia”, “international normalised ratio” and similar terms are either glossed or unavoidable decision-gate terminology.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, tier item and table cell is a short phrase; no full explanatory sentences outside the fixed footer.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan for “you”/”your”/”we”/”our” — no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets (hs-CRP below 0.5 mg/L, triglycerides below 80 mg/dL, HbA1c 4.8-5.4%) are optimisation ranges, not conventional cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	The anti-inflammatory dose of 14-28 g of oil daily and the 12-month nerve endpoint horizon are presented without dilution.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, fatty-acid panels and a 14-day pre-procedure stop assume a committed user.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance foregrounds that target engagement is reliable while clinical benefit is narrow — the distinction this audience needs.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal upset”, “intrapartum”, “antiplatelet”, “dihomo-gamma-linolenic acid” — consistently formal register carried from the ER.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified byte-identical to the template at lines 445, 488, 537, 571, 592, 616, 641, 645-647, 782 and the four tier labels in both tier lists.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variables present; the indexed marker_#_* and qualitative_item_# placeholders are expanded to 8 marker rows and 7 qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows differences only inside data-qrs-var spans; the stylesheet, layout, comments and footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section drawn on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“General supplementation dose”, “Anti-inflammatory dose” and “Split dosing rather than a single dose” match the ER bold labels at lines 362, 364 and 372 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk items reuse ER heading text; marker names reuse the ER biomarker-table names; time-to-effect labels are drawn from the ER’s own wording at line 421 (“nerve endpoints”, “skin and joint endpoints”, membrane fatty-acid plateau).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s tier emoji and “⚠️ Conflicted” markers are correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content is held to the template’s per-section budget: tier lists are single-line joins, gate and qualitative items are trimmed phrases, and marker “Why” cells are reduced to four-to-eight-word fragments.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2-14, immediately after <!doctype html> at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding “QRS — Metadata” text sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of the values are repeated in the header, body or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: evening_primrose_oil_2026-0825-2333_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0818-0207.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Evening Primrose Oil for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Evening Primrose Oil for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/18/2026”, correctly derived from 2026-0818-0207.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s fixed subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434-437 condense ER lines 496-498: target engagement, the three strongest clinical signals, the two failed indications, the two main hazards.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence of ER lines 496-498; “modest blood-fat lowering in people starting abnormal” mirrors “a modest lowering of blood fats in people who start with abnormal readings”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“uncommon fat”, “blood and cell membranes”, “nerve-symptom relief”, “blood-fat lowering” — no acronyms and no specialist classifications.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year or sample size named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items map to the ER’s “Populations who should avoid Evening Primrose Oil” list at lines 332-340.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-list bullets are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 574-587: five discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s explanatory glosses (“placenta covering the cervix”, “both inherited clotting-factor deficiencies”) are stripped and no dash-trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“before 37 completed weeks”, “below 50 x 10⁹/L”, “within 14 days”, “above 3.0”, “within 90 days” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication bullets.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five avoid populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER interaction bullets at lines 314-326.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets are carried; the eighth (“surgery, dental extraction and cosmetic procedures”, ER line 328) is correctly omitted because it is already a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 595-606: seven discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER rationale clause after the colon is stripped; the ER’s inline gloss “medicines that suppress HIV” is removed and no dash-trailing clause remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named example-drug lists retained verbatim (warfarin/apixaban/rivaroxaban/dabigatran; clopidogrel/ticagrelor/prasugrel; ibuprofen/naproxen; chlorpromazine/fluphenazine/thioridazine; lopinavir/ritonavir; the seven bleeding-potentiating supplements; zinc/magnesium/vitamin B6).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 362, 364 and 372.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The default dose, the anti-inflammatory dose, and the dosing pattern — the three bullets that determine what a user actually takes and how.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains thirteen bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; values and subs match ER lines 362, 364 and 372 including the 70-300 mg and 14-28 g conversions.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Membrane fatty-acid plateau (4-8 weeks), nerve endpoints (12 months) and skin/joint endpoints (8-24 weeks) are exactly the three horizons the ER gives at lines 376 and 421.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High tier (dihomo-gamma-linolenic acid rise) → Medium tier (diabetic neuropathy) → Medium/Low tier (rheumatoid arthritis and skin).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides more than three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated; sub-lines trace to ER lines 376 (“Plasma gamma-linolenic acid clears in hours”), 366 (“required a full year before endpoints separated”) and 399 (12-week reassessment trigger).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at lines 376, 391 and 421, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve items correspond one-to-one with the ER benefit headings at lines 158-230.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 539-564, tiers matching the ER exactly (1 high, 4 medium, 5 low, 2 speculative).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER benefit heading reduced to sentence case; no magnitude figures, confidence intervals or study references carried across.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven items correspond one-to-one with the ER risk headings at lines 254-296.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 618-635, tiers matching the ER exactly (1 high, 3 medium, 1 low, 2 speculative).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER risk heading reduced to sentence case; the 20%-versus-3% event rate, relative risk and case-report detail are all left out.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows map to the ER biomarker table at lines 449-458.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present with matching targets: dihomo-gamma-linolenic acid, arachidonic-to-eicosapentaenoic ratio 3:1, hs-CRP below 0.5 mg/L, triglycerides below 80 mg/dL, HDL above 55/45 mg/dL, INR 2.0-3.0, platelets 150-400 x 10⁹/L, HbA1c 4.8-5.4%.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 772-776 reproduce the ER’s cadence at line 447: baseline, 12 weeks, 6 and 12 months, plus the 1-2 week warfarin recheck.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items map to the ER’s “Qualitative markers worth tracking” list at lines 462-474.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present verbatim, none omitted or added.

Issues 18/08/2026 02:33

Pass rate 100.00%. No issues found.

Issues 18/08/2026 02:25

1. 4.5 — Sheet exceeds one A4 page: At the template’s own type sizes the rendered stack is roughly twice the printable A4 height, driven mainly by the Monitoring card, whose eight Target/Why cells and cadence line are carried near-verbatim from the ER table (ER lines 447-458), plus verbose [at_a_glance], gate items and [action_#sub]/[time#_sub] cells.

Fixes 18/08/2026 02:25

1. 4.5 — Monitoring table cells condensed: Tightened all eight Why cells and the verbose Target cells (e.g. marker_1_why “Confirms the oil is actually being absorbed and converted” to “Confirms absorption and conversion”; marker_6_target “Within the target set for the underlying indication, typically 2.0-3.0” to “Indication-specific target, typically 2.0-3.0”), and shortened marker_1_name and marker_1_target, cutting the tallest card on the sheet without dropping any of the eight biomarkers.

2. 4.5 — Monitoring cadence tightened: Trimmed [monitoring_cadence] from the near-verbatim ER sentence to “Baseline before starting; fatty-acid panel and inflammation marker at 12 weeks; lipids and inflammation at 6 and 12 months; on warfarin, clotting-time ratio 1-2 weeks after starting or stopping and after any dose change.”

3. 4.5 — Protocol and time-to-effect subs shortened: Condensed action_1_sub, action_2_sub, time_1_sub and time_3_sub (e.g. “Honest assessment takes months; no movement by 12 weeks at an adequate dose argues against continuing” to “No movement by 12 weeks at an adequate dose argues against continuing”), removing a wrapped line from each protocol grid row.

4. 4.5 — Contraindication item trimmed: Shortened the anticoagulation gate item to “Anticoagulation above target (international normalised ratio above 3.0) or significant bleed within 90 days”, keeping the threshold and the 90-day window intact.

Issues 18/08/2026 02:19

1. 7.3 — At-a-glance narrows the ER claim: [at_a_glance] (line 435) states “nerve-pain relief in diabetes”, but the ER Conclusion (line 496) and the matching benefit heading say “symptom relief in diabetic nerve damage” / total symptom score, not pain relief specifically.
2. 2.8 — Time-to-effect sub restates its own cell: [time_3_sub] (lines 528-531) repeats [time_3_label] (“Skin and joint endpoints”) and [time_3_value] (“8-24 weeks”) verbatim, leaving only “so honest assessment takes months” as new information.

Fixes 18/08/2026 02:19

1. 7.3 — At-a-glance claim aligned to ER: Changed “nerve-pain relief in diabetes” to “nerve-symptom relief in diabetes” in [at_a_glance], matching the ER Conclusion’s “symptom relief in diabetic nerve damage”.
2. 2.8 — Time-to-effect sub de-duplicated: Replaced [time_3_sub] “Skin and joint endpoints were assessed at 8-24 weeks, so honest assessment takes months” with “Honest assessment takes months; no movement by 12 weeks at an adequate dose argues against continuing”, removing the restatement of the label and value.

Issues 18/08/2026 02:11

1. 11.4 — Time-to-effect sub mismatched: [time_3_sub] at line 529 carries “Protocols are judged at 8-12 weeks, not days”, which the ER attaches to membrane dihomo-gamma-linolenic acid turnover rather than to skin and joint endpoints, and it contradicts the same cell’s value of “8-24 weeks”.

Fixes 18/08/2026 02:11

1. 11.4 — Time-to-effect sub mismatched: Replaced [time_3_sub] “Protocols are judged at 8-12 weeks, not days” with “Skin and joint endpoints were assessed at 8-24 weeks, so honest assessment takes months”, drawn from the ER Practical Considerations bullet that actually covers these endpoints. This removes the contradiction with the cell’s “8-24 weeks” value.